NCT06161922View on ClinicalTrials.gov

Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy

RecruitingOBSERVATIONAL

Enrollment

600

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions

HER2-positive Breast Cancer

Trial Locations (1)

Unknown

RECRUITING

Keda Yu, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER